undamentalytics Newsletter
Sign in

Acadia Pharmaceuticals Inc cash flow statement

In fiscal 2025, Acadia Pharmaceuticals Inc's operations generated $110m of cash; it spent $4.7m on capital projects, leaving free cash flow of $105m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−14−11−20−22−32−66−122−208−218−167−151−136−126−11417158110160
Depreciation and amortisation110000111211221111
Stock-based pay2222616405576828284646866675258
Capital spending——0—102212181001515
Free cash flow——−20—−32−67−124−210−219−170−152−144−127−11417157105146
Free cash flow after stock pay——−21—−38−83−164−265−294−251−235−228−190−182−50905388
Shares issued2114981122041551931307372811882575047

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ACAD vs PTCTACAD vs LKFTACAD vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Acadia Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Acadia Pharmaceuticals Inc.